FR3026744B1 - Methode de generation de progeniteurs de cellules t - Google Patents

Methode de generation de progeniteurs de cellules t Download PDF

Info

Publication number
FR3026744B1
FR3026744B1 FR1459539A FR1459539A FR3026744B1 FR 3026744 B1 FR3026744 B1 FR 3026744B1 FR 1459539 A FR1459539 A FR 1459539A FR 1459539 A FR1459539 A FR 1459539A FR 3026744 B1 FR3026744 B1 FR 3026744B1
Authority
FR
France
Prior art keywords
cell progenitors
paris
ligand
generation
institute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1459539A
Other languages
English (en)
French (fr)
Other versions
FR3026744A1 (fr
Inventor
Emmanuelle Six
Marina Cavazzana
Isabelle Andre
Chantal Lagresle-Peyrou
Salima Hacein-Bey-Abina
Christian Reimann
Chappedelaine Corinne De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine Institut Des Maladies Gene Fr
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Fondation Imagine Inst Des Maladies Genetiques
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1459539A priority Critical patent/FR3026744B1/fr
Application filed by Fondation Imagine Inst Des Maladies Genetiques, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Fondation Imagine Inst Des Maladies Genetiques
Priority to HUE15771979A priority patent/HUE059468T2/hu
Priority to PT157719790T priority patent/PT3204492T/pt
Priority to ES15771979T priority patent/ES2914082T3/es
Priority to CA2963756A priority patent/CA2963756C/fr
Priority to DK15771979.0T priority patent/DK3204492T3/da
Priority to PCT/EP2015/072889 priority patent/WO2016055396A1/fr
Priority to PL15771979.0T priority patent/PL3204492T3/pl
Priority to JP2017537016A priority patent/JP6898240B2/ja
Priority to EP22152734.4A priority patent/EP4036224A1/fr
Priority to US15/516,731 priority patent/US12071635B2/en
Priority to EP15771979.0A priority patent/EP3204492B1/fr
Publication of FR3026744A1 publication Critical patent/FR3026744A1/fr
Priority to JP2020209370A priority patent/JP2021072779A/ja
Application granted granted Critical
Publication of FR3026744B1 publication Critical patent/FR3026744B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
FR1459539A 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t Active FR3026744B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t
US15/516,731 US12071635B2 (en) 2014-10-06 2015-10-05 Method for generating T-cell progenitors
ES15771979T ES2914082T3 (es) 2014-10-06 2015-10-05 Procedimiento de generación de progenitores de células T
CA2963756A CA2963756C (fr) 2014-10-06 2015-10-05 Methode de generation de progeniteurs de cellules t
DK15771979.0T DK3204492T3 (da) 2014-10-06 2015-10-05 Fremgangsmåde til generering af t-celleforløbere
PCT/EP2015/072889 WO2016055396A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
HUE15771979A HUE059468T2 (hu) 2014-10-06 2015-10-05 Módszer T-sejt progenitorok generálására
JP2017537016A JP6898240B2 (ja) 2014-10-06 2015-10-05 Ｔ細胞前駆細胞を生成するための方法
EP22152734.4A EP4036224A1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
PT157719790T PT3204492T (pt) 2014-10-06 2015-10-05 Método de geração de progenitores de células t
EP15771979.0A EP3204492B1 (fr) 2014-10-06 2015-10-05 Méthode de génération de progéniteurs de cellules t
PL15771979.0T PL3204492T3 (pl) 2014-10-06 2015-10-05 Sposób generowania komórek progenitorowych limfocytów t
JP2020209370A JP2021072779A (ja) 2014-10-06 2020-12-17 Ｔ細胞前駆細胞を生成するための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1459539A FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t

Publications (2)

Publication Number Publication Date
FR3026744A1 FR3026744A1 (fr) 2016-04-08
FR3026744B1 true FR3026744B1 (fr) 2024-04-19

Family

ID=52102849

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1459539A Active FR3026744B1 (fr) 2014-10-06 2014-10-06 Methode de generation de progeniteurs de cellules t

Country Status (11)

Country Link
US (1) US12071635B2 (https=)
EP (2) EP3204492B1 (https=)
JP (2) JP6898240B2 (https=)
CA (1) CA2963756C (https=)
DK (1) DK3204492T3 (https=)
ES (1) ES2914082T3 (https=)
FR (1) FR3026744B1 (https=)
HU (1) HUE059468T2 (https=)
PL (1) PL3204492T3 (https=)
PT (1) PT3204492T (https=)
WO (1) WO2016055396A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017173551A1 (en) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
WO2023079082A1 (en) 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
KR20250152088A (ko) 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
KR20260041821A (ko) 2023-07-12 2026-03-27 메이라지티엑스 셀 테라피스 특이적 동형접합성 hla 일배체형을 갖는 세포 뱅크의 바이오뱅크 및 환자 치료를 위한 이의 용도
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
WO2025255678A1 (en) * 2024-06-14 2025-12-18 Stemcell Technologies Canada Inc. Compositions and methods for generating lymphoid lineage cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
KR101331746B1 (ko) * 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
EP2331679B1 (en) 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
AU2009311232B2 (en) 2008-11-07 2014-10-30 Sunnybrook Health Sciences Centre Human progenitor T-cells
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
CA2795627C (en) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2014110353A1 (en) * 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
WO2016039933A1 (en) * 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders

Also Published As

Publication number Publication date
US20180208895A1 (en) 2018-07-26
EP3204492A1 (fr) 2017-08-16
PL3204492T3 (pl) 2022-07-25
JP2021072779A (ja) 2021-05-13
EP4036224A1 (fr) 2022-08-03
FR3026744A1 (fr) 2016-04-08
ES2914082T8 (es) 2022-06-16
PT3204492T (pt) 2022-05-30
JP6898240B2 (ja) 2021-07-07
DK3204492T3 (da) 2022-06-07
US12071635B2 (en) 2024-08-27
WO2016055396A1 (fr) 2016-04-14
CA2963756A1 (fr) 2016-04-14
JP2017531448A (ja) 2017-10-26
ES2914082T3 (es) 2022-06-07
HUE059468T2 (hu) 2022-12-28
CA2963756C (fr) 2024-01-02
EP3204492B1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
FR3026744B1 (fr) Methode de generation de progeniteurs de cellules t
Privat-Maldonado et al. Modifying the tumour microenvironment: Challenges and future perspectives for anticancer plasma treatments
JOP20220225B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
CY1121236T1 (el) Ανθρωπινα αντισωματα εναντι της pcsk9 για χρηση σε μεθοδους θεραπειας συγκεκριμενων ομαδων ατομων
Zhang et al. Cyclic mechanical stretching promotes migration but inhibits invasion of rat bone marrow stromal cells
Wolff et al. Combination treatment with cold physical plasma and pulsed electric fields augments ROS production and cytotoxicity in lymphoma
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
CY1126148T1 (el) Καινοτομος χιμαιρικη πρωτεϊνη ειδικη για τις cd137 και pd-l1
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
MA49727B1 (fr) Anticorps et polypeptides dirigés contre cd127
Stańczyk et al. The promising potential of cold atmospheric plasma therapies
DOP2015000162A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
MX388202B (es) Métodos para generar productos de esmalte in vitro.
MX2019012461A (es) Anticuerpo anti-pd-l1 y uso del mismo.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
Zubor et al. Cold atmospheric pressure plasma (CAP) as a new tool for the management of vulva cancer and vulvar premalignant lesions in gynaecological oncology
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
CY1115223T1 (el) Αντι-μελαγχολικο φαρμακο που παρασκευαζεται με υλικα camp απο τζιτζιφα
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
EP4382123A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SMALL CELL LUNG CANCER
Mohamed et al. Immunomodulatory effects of non-thermal plasma in a model for latent HIV-1 infection: implications for an HIV-1-specific immunotherapy
La Rocca et al. Mechanical stress downregulates MHC class I expression on human cancer cell membrane
PL379549A1 (pl) Autologiczne, indukujące tolerancję na antygeny własne komórki pochodzenia monocytarnego oraz ich zastosowanie w preparatach farmaceutycznych

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20160408

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

CD Change of name or company name

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20221006

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20221006

Owner name: FONDATION IMAGINE - INSTITUT DES MALADIES GENE, FR

Effective date: 20221006

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Effective date: 20221006

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12